Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:AYTU NASDAQ:EXOZ NASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$9.07-3.1%$5.78$3.39▼$16.00$119.27M0.8108,214 shs105,289 shsAYTUAytu BioPharma$2.29+1.8%$2.24$0.95▼$2.85$20.56M0.13619,835 shs103,324 shsEXOZeXoZymes$9.99-0.4%$10.67$8.50▼$23.99$83.60MN/A14,787 shs2,415 shsVXRTVaxart$0.38+1.2%$0.44$0.26▼$1.07$88.02M1.123.10 million shs729,995 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+3.88%+14.15%+95.82%+160.00%-5.45%AYTUAytu BioPharma+0.45%-9.27%+3.21%+66.67%-5.06%EXOZeXoZymes+1.72%-0.59%+2.24%-29.47%+1,002,999,900.00%VXRTVaxart+4.79%+5.45%-13.58%-3.25%-33.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics2.4678 of 5 stars3.53.00.00.01.61.70.6AYTUAytu BioPharma3.7647 of 5 stars3.52.00.03.43.30.00.6EXOZeXoZymesN/AN/AN/AN/AN/AN/AN/AN/AVXRTVaxart2.7452 of 5 stars3.55.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00230.76% UpsideAYTUAytu BioPharma 3.00Buy$10.00336.68% UpsideEXOZeXoZymes 0.00N/AN/AN/AVXRTVaxart 3.00Buy$3.00680.23% UpsideCurrent Analyst Ratings BreakdownLatest AYTU, AVTX, VXRT, and EXOZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025AYTUAytu BioPharmaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.006/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.00(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K271.07N/AN/A$7.95 per share1.14AYTUAytu BioPharma$81.66M0.25N/AN/A$4.64 per share0.49EXOZeXoZymesN/AN/AN/AN/A$1.25 per shareN/AVXRTVaxart$47.40M1.86N/AN/A$0.26 per share1.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A-48.48%-35.94%N/AAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%9/25/2025 (Estimated)EXOZeXoZymes-$5.86MN/A0.00∞N/AN/AN/AN/AN/AVXRTVaxart-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/13/2025 (Estimated)Latest AYTU, AVTX, VXRT, and EXOZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025VXRTVaxart-$0.08N/AN/AN/A$2.03 millionN/A8/12/2025Q2 2025EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A8/7/2025Q2 2025AVTXAvalo Therapeutics-$1.43-$1.92-$0.49-$1.92N/AN/A5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million5/13/2025Q1 2025VXRTVaxart-$0.07-$0.07N/A-$0.07$2.85 million$20.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A12.4412.44AYTUAytu BioPharma0.271.030.87EXOZeXoZymesN/A6.526.52VXRTVaxartN/A0.640.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%AYTUAytu BioPharma33.49%EXOZeXoZymesN/AVXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.25%AYTUAytu BioPharma3.60%EXOZeXoZymes72.41%VXRTVaxart2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4013.15 million13.12 millionNot OptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableEXOZeXoZymes298.37 million2.31 millionN/AVXRTVaxart120228.92 million222.37 millionOptionableAYTU, AVTX, VXRT, and EXOZ HeadlinesRecent News About These CompaniesUS orders Vaxart to stop COVID-19 trial amid mRNA wind down1 hour ago | reuters.comVaxart (NASDAQ:VXRT) Stock Price Passes Below 200-Day Moving Average - Here's WhyAugust 7, 2025 | marketbeat.comVaxart (VXRT) Expected to Announce Earnings on ThursdayAugust 7, 2025 | marketbeat.comVaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split ProposalJuly 31, 2025 | quiverquant.comQVaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Here's WhyJuly 29, 2025 | marketbeat.comVaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on NasdaqJuly 24, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?July 19, 2025 | marketbeat.comOTC Markets Group Welcomes Vaxart, Inc. to OTCQXJuly 8, 2025 | financialpost.comFVaxart Announces Preliminary Results of Annual Meeting of StockholdersJune 13, 2025 | globenewswire.comVaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation TechnologyJune 11, 2025 | globenewswire.comVaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025June 10, 2025 | quiverquant.comQVaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus TrialJune 10, 2025 | globenewswire.comVaxart Announces Adjournment of Annual Meeting of StockholdersJune 2, 2025 | globenewswire.comVaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025May 29, 2025 | globenewswire.comVaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025May 29, 2025 | quiverquant.comQVaxart's Founder and Chief Scientific Officer Provides Video Update to StockholdersMay 29, 2025 | globenewswire.comVaxart Discusses Reverse Stock Split and Capital RaiseMay 28, 2025 | tipranks.comVaxart Answers Additional Frequently Asked Questions from Retail InvestorsMay 28, 2025 | globenewswire.comVaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 27, 2025 | globenewswire.comVaxart Announces Adjournment of Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comVaxart, Inc. Grants Equity Awards to New CFO Jeroen GrasmanMay 20, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYTU, AVTX, VXRT, and EXOZ Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$9.07 -0.29 (-3.10%) Closing price 04:00 PM EasternExtended Trading$8.93 -0.14 (-1.59%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Aytu BioPharma NASDAQ:AYTU$2.29 +0.04 (+1.78%) Closing price 04:00 PM EasternExtended Trading$2.32 +0.03 (+1.31%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.eXoZymes NASDAQ:EXOZ$9.99 -0.04 (-0.40%) As of 02:13 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Vaxart NASDAQ:VXRT$0.38 +0.00 (+1.18%) As of 03:59 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Rocket Lab Scores Analyst Upgrades, Finalizes Geost Takeover Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAE Intel's White House Reset: From Political Storm to a Clearer Sky On Holdings: Correction Is Over, the Sprint to Highs Is On Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.